bydureon bcise
Bydureon Bcise (Exenatide Synthetic) is a medication used to treat Type 2 Diabetes Mellitus.
Exenatide Synthetic · by Astrazeneca Ab
Key facts
- Active ingredient
- Exenatide Synthetic
- Form
- Suspension, extended release
- Strength
- Exenatide Synthetic 2MG/0.85ML (2MG/0.85ML)
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- type 2 diabetes mellitus
- Manufacturer
- Astrazeneca Ab
- FDA application
- NDA209210
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Suspension, extended release
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Bydureon Bcise treat?
- Bydureon Bcise (Exenatide Synthetic) may be used to treat type 2 diabetes mellitus, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- Is there a coupon or discount for Bydureon Bcise?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Bydureon Bcise. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Bydureon Bcise?
- Bydureon Bcise is marketed by Astrazeneca Ab. You can see Astrazeneca Ab's full profile, rating, and other products on pharmaranks.
- Is Bydureon Bcise a brand-name or generic drug?
- Bydureon Bcise is a brand-name product with the active ingredient Exenatide Synthetic.
- Is Bydureon Bcise available over the counter?
- No. Bydureon Bcise is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Bydureon Bcise come in?
- Bydureon Bcise is currently marketed as suspension, extended release, per the FDA's National Drug Code Directory.
- Is Bydureon Bcise FDA-registered?
- Bydureon Bcise is on record with the U.S. FDA under application number NDA209210. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about EXENATIDE SYNTHETIC
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1 reports naming EXENATIDE SYNTHETIC — the active ingredient in Bydureon Bcise, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- cataract1 reports
- chest pain1 reports
- coronary artery occlusion1 reports
- eye haemorrhage1 reports
- retinopathy1 reports
Read these as a signal, not a rate. A report does not mean EXENATIDE SYNTHETIC caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
brynovin
Sitagliptin Hydrochloride
invokana
Canagliflozin
merilog
Insulin Aspart-Szjj
merilog solostar
Insulin Aspart-Szjj
rezvoglar
Insulin Glargine-Aglr
tradjenta
Linagliptin
Compare Bydureon Bcise head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
bydureon bcise
New